Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00007891 · ClinicalTrials.gov registry record · Phase 1

Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

A Phase 1 study of Breast Cancer, sponsored by Cancer Research Institute of Contra Costa.

Completed
Registry status
Phase 1
Development phase
2
Study locations

NCT00007891: Completed Phase 1 study of Breast Cancer, sponsored by Cancer Research Institute of Contra Costa.

NCT00007891 is a Phase 1 study of Breast Cancer that has completed, run by Cancer Research Institute of Contra Costa. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00007891, a Phase 1 study of Breast Cancer, has completed, sponsored by Cancer Research Institute of Contra Costa.

COMPLETED
Registry status
Phase 1
Development phase
2
Study locations

Study Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation or bone marrow transplantation may be able to replace immune cells that were destroyed by monoclonal antibody therapy used to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy followed by bone marrow or peripheral stem cell transplantation in treating patients who have metastatic breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • PROCEDURE peripheral blood stem cell transplantation
  • BIOLOGICAL filgrastim
  • PROCEDURE autologous bone marrow transplantation
  • RADIATION indium In 111 monoclonal antibody BrE-3
  • RADIATION yttrium Y 90 monoclonal antibody BrE-3

Study Locations (2)

California

  • Cancer Research Institute of Contra Costa - San Francisco

Colorado

  • University of Colorado Cancer Center at University of Colorado Health Sciences Center - Aurora

Trial Details

FieldValue
Start Date 1997-06
Est. Completion 2004-10
Phase Phase 1

Sponsor

Cancer Research Institute of Contra Costa

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00007891

The ClinicalTrials.gov registry entry for NCT00007891 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Cancer Research Institute of Contra Costa, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which peripheral blood stem cell transplantation is the first listed.

NCT00007891 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Colorado.

Frequently Asked Questions

What is clinical trial NCT00007891 about?

NCT00007891 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation or bone marrow transplantation may be able to replace immune cells that were destroyed by monoclona...

What is the current status of trial NCT00007891?

This trial is currently completed. It is a Phase 1 study. The study started on 1997-06. Estimated completion is 2004-10.

What conditions does trial NCT00007891 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00007891?

The interventions under investigation include: peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), autologous bone marrow transplantation (PROCEDURE), indium In 111 monoclonal antibody BrE-3 (RADIATION), yttrium Y 90 monoclonal antibody BrE-3 (RADIATION).

Who is sponsoring clinical trial NCT00007891?

This trial is sponsored by Cancer Research Institute of Contra Costa, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00007891 being conducted?

This trial has 2 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.